Northern, WI 9/13/2011 (PennyPayDay) – www.InvestorIdeas.com, a global investor research portal for independent investors issues a report for biotech and pharma stocks to watch based on trading and news for 12th September .U.S. markets ended higher after falling sharply earlier in the trading session boosted by some reports that China could rescue European debt markets. Bitotechnology stocks were among the top per performers with the NASDAQ Biotechnology Index climbing 6.6 or 0.71% to $982.57, near the day’s high of 982.84.
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) shares ended higher by 0.73% to $2.77 after hitting a day’s high of $2.90. On Monday, the company announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study. The top-line results indicate that LibiGel increases levels of free testosterone, bioavailable testosterone and total testosterone in the serum of postmenopausal women to within the normal ranges for younger, premenopausal women.
RXi Pharmaceuticals Corporation (NASDAQ:RXII) was one of the top biggest gainers and moved 14 cents or 14% to $1.14, off day’s high of $1.28. The company announced that the FDA has expanded a partial clinical hold on the company’s NeuVax, which had been earlier delaying a late-stage study.
Dendreon Corporation (NASDAQ:DNDN) shares rose 29 cents or 2.54% to $11.69, recovering from day’s low of $10.89. Analyst at Roth Capital has downgraded the stock to Neutral from Buy. Also, an analyst at ThinkEquity reduced its price target on the stock to $21 with a buy rating.
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) jumped 17 cents or 13.46% to close at day’s high of $1.45. More than 70.5K shares traded hands, compared to its average volume 31.13K shares. The stock moved following an article from Seekingalpha, which listed the stock as a top ceap biotech stocks that could double or triple by next year.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Showcase Biotech/Pharma stock at Investorideas.com:
BioSante Pharmaceuticals, Inc.
http://www.biosantepharma.com/
Read the August 2011 Fact Sheet in Full
http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please contact:
For Investors: For Media:
The Trout Group LLC McKinney/Chicago
Tricia Swanson Alan Zachary
(646) 378-2953; tswanson@troutgroup.com 312-506-5220; azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
http://www.investorideas.com/CO/BPAX/
Request news, updates and trading alerts on BPAX http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: The following investor idea and featured is a not a recommendation, but a profile of one of many publicly traded biotech and pharma stocks for investors to research. Disclosure: BPAX is a featured showcase stock and compensates Investorideas.com (six thousand five hundred for three months advertising) our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
800-665-0411 – dawn@investorideas.com or cvanzant@investorideas.com
Source – Investorideas.com
PennyPayDay Disclaimer
No comments:
Post a Comment